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Abstract. The efficacy of HSV-TK/ganciclovir-based gene
therapy on malignant gliomas largely relies on the amplitude
of the bystander effect. In these experiments, the anti-
inflammatory drug Sulfasalazine increased the HSV-TK/
ganciclovir bystander effect in C6, 9L and LN18 cells but not
in U87 glioma cells. Using bi-compartmental culture devices
and conditioned medium transfer experiments, we showed that
in C6, 9L and LN18 cells but not in U87 cells, Sulfasalazine
also unveiled a new, contact-independent mechanism of
HSV-TK/ganciclovir bystander effect. Upon treatment with
ganciclovir, human LN18-TK but not U87-TK cells synthetized
and released TNF-· in the culture medium. Sulfasalazine
sensitized glioma cells to the toxic effect of TNF-· and
enhanced its secretion in LN18-TK cells in response to GCV
treatment. The caspase-8 inhibitor Z-IETD-FMK and a
blocking antibody to TNF-· both inhibited the contact-
independent bystander effect in LN18 cells. Taken together,
these results suggest that TNF-· mediates the contact-
independent bystander effect in LN18 cells. The treatment
with GCV and/or Sulfasalazine of tumor xenografts
consisting of a mix of 98% C6 and 2% C6-TK cells shows
that Sulfasalazine is also a potent adjunct to the in vivo
treatment of gliomas.
Introduction
The efficacy of Herpes virus thymidine kinase/ganciclovir
suicide gene therapy largely depends on the ability of trans-
fected cells to kill neighboring untransfected cancer cells, a
process called the bystander effect. This effect explains the
complete regression of some experimental tumors where only
one tenth of the cells are transfected with the suicide gene
(1,2), and is believed to arise notably from the diffusion of
phosphorylated ganciclovir molecules through gap junctions
between transfected and untransfected cancer cells (3-5).
Additional mechanisms may also contribute to this bystander
effect, such as the phagocytosis of transfected cell debris
containing thymidine kinase or the release of yet undefined
diffusible death signals (6,7). In vivo, immune mechanisms
and vascular occlusion resulting from endothelial cell damage
may also occur (8-10). As a wealth of glial tumors display low
levels of gap junctional intercellular communication (11), the
characterization of the multiple molecular pathways underlying
the bystander effect is paramount, and is a prerequisite to the
improvement of current gene therapy protocols.
Recent evidence suggests that ligand-independent clustering
of a TNF-receptor family death receptor, FAS/CD95, con-
tributes to chemotherapy-induced apoptotic death of cancer
cells, and might occur in HSV-tk expressing cells treated
with ganciclovir (12). Although one study also suggests that
FAS ligand-dependent activation of this same receptor might
participate to the bystander effect of some cell types (13), the
question of the implication of death receptors in the genesis
of the bystander effect remains largely unanswered. Death
receptor activation in fact triggers both caspase-8 dependent
apoptosis and an NF-κB-dependent anti-apoptotic cascade in
a variety of tumors, including malignant gliomas (14-16).
Since the balance between these pro- and anti-apoptotic
cascades appears to be altered in glioblastomas (17), we have
sought to establish whether Sulfasalazine, a known NF-κB
inhibitor (18) and modulator of death receptor function (19),
could enhance the efficacy of HSV-TK/ganciclovir gene
therapy in gliomas.
Materials and methods
Cell cultures. C6 cells (ATCC) were kept in DMEM supple-
mented with 3% fetal bovine serum (FBS) and penicillin
(DEM-C). 9L cells (gift from Dr C. Grignet, Liège, Belgium),
LN18 cells (obtained from Dr N. De Tribolet) and U87 cells
(ATCC) were grown in RPMI-1640 containing L-glutamine
and supplemented with 10% FBS and penicillin (RPMI-C).
Clones LN18-TK, C6-TK and U87-TK were obtained by
transfection with a defective murine retrovirus carrying the
HSV-tk and the geneticin resistance genes (gift of Dr C.
Grignet), selection in G418, and clonal expansion and selected
on the basis of their sensitivity to ganciclovir and of their
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growth characteristics similar to those of parental LN18, C6
and U87 cells, respectively (20,21). Clone 9L-TK was a gift
from Dr C. Grignet (22). All clones were kept in RPMI-C or
DEM-C supplemented with G418. 
Cytotoxicity assay. Cytotoxicity assays were performed strictly
as described previously (13,20,21). Cells were grown on 96-
well plates for various periods of time and treated with GCV
or TNF-· in the presence or not of sulfaslazine (0.5 mM).
MTT assay was then performed. Survival of GCV-treated
cells was expressed in percents of the survival of GCV-free
cells. Survival of GCV and Sulfasalazine-treated cells was
expressed as percentage of the survival of Sulfasalazine-only
treated cells. Survival of TNF·-treated cells was expressed as
percentage of the survival of TNF·-free cells. Survival of
TNF· + Sulfasalazine-treated cells was expressed as
percentage of the survival of Sulfasalazine-only treated cells.
Assessment of the bystander effect in mixed cultures. The
bystander effect was also assessed as described previously
(13,20,21). Briefly, TK+ and TK- cells were mixed in various
proportions and grown in RPMI-C. Treatment conditions
were set as described in the results section, media were
changed every two days, and the MTT test was used on day 5
to assess total cell survival (23). Survival of GCV-treated
cells was expressed as percentage of the survival of GCV-
free cells. Survival of GCV + Sulfasalazine-treated cells was
expressed as percentage of the survival of Sulfasalazine-only
treated cells.
Electric mobility shift assay. Electrical mobility shift assays
(EMSA) were performed on nuclear protein extracts as
described previously (16) using an oligonucleotide probe
identical to the human immunodeficiency virus κB element
(5'-GATCAGGGACTTTCCGCTGGGGACTTTCCAG-3')
that was annealed with its complementary strand and end-
labeled with [32P]-ATP. Negative (competition) controls were
performed with nuclear extracts from HCT-116 cells stimulated
with TNF-· for 30 min and in the presence of an excess of
unlabeled probe, whereas positive controls were performed
with these same extracts in the presence of an excess of
mutant probe (5'-GATCACTCACTTTCCGCTGCTCACTT
TCCAG-3').
TNF-· ELISA. LN18-TK or U87-TK cells (106) were grown
in RPMI medium in the presence or absence of Sulfasalazine
(0.5 mM) for 72 h in 35-mm dishes, and GCV was added at
various time-points without replacing the medium. Supernatants
were centrifuged to eliminate cell debris and processed with
a TNF-· ELISA kit (Peprotech, Rocky Hill, NJ) according to
the manufacturer's instructions.
Quantitative RT-PCR. TNF-· mRNA levels were determined
with reverse transcription-polymerase chain reaction (RT-PCR)
(24) using a TaqMan® (Stratagene, La Jolla, CA) real-time
PCR device. Total RNA was extracted from glioma cells using
RNEasy columns (Qiagen, Valencia, CA), according to the
manufacturer's instructions. Recovered RNA was quantified
by spectrometry (Gene Quant, Pharmacia, Piscataway, NJ),
and 2 μg of RNA was subjected to reverse transcription using
the SuperScript First-Strand Synthesis system for RT-PCR
(Invitrogen Life Technologies, Paisley, UK). The newly
transcribed complementary DNA (cDNA) was amplified by
TaqMan quantitative PCR according to the manufacturer's
instructions and using SYBR green 1 dye.
Primers were designed to amplify a 227-bp segment on
exons 2, 3 and 4 of TNF-· (sense: CCCAGGCAGTCAGATC
ATCTTC and antisense: TGGTTATCTCTCAGCTCCACGC)
and were standardized with respect to ABL expression.
Assessment of the gap junction intercellular communication
(GJIC). FACS analysis of the GJIC was performed as described
elsewhere (21). Briefly, cells grown in Petri dishes for 24 h
in the presence or absence of Sulfasalazine were labelled
for one hour with either gap-junction diffusible calcein or
permanent cytoplasmic dye CMTMR in PBS, rinsed and then
mixed at a total density of 2x106 cells/6 cm Petri dish. After
another 4-h period in the presence or absence of Sulfasalazine,
they were trypsinized, collected in PBS and processed for
FACS analysis to evidence the diffusion of calcein to CMTMR-
stained cells. 
Medium transfer experiments. TK+ cells were grown for
48-96 h at confluence in 5-ml/9-cm Petri dishes in the
presence or absence of GCV (10 μM) and/or Sulfasalazine
(0.5 mM). Media were then collected, centrifuged at 5000
RPM. Supernatants were filtered on Millex® filters (Millipore,
Brussels, Belgium) and transferred for 24 h on 104 TK- cells
grown in 96-well plates. Cell survival was then assessed with
the MTT test. Controls were set as follows: conditioned
medium from untreated TK+ cells for GCV-treated TK+ cells,
and conditioned medium from Sulfasalazine-treated cells for
GCV + Sulfasalazine treated TK+ cells. Survival was expressed
as percentage of the survival in these control conditions. In
some experiments, the caspase-8 inhibitor Z-IETD-FMK (30
μM) or a blocking antibody to TNF-· (25-50 ng/ml) were
added to the conditioned media immediately prior to its
transfer onto TK- cells.
Bi-compartmental cultures. For each cell type, 20,000 TK- cells
were seeded in a 24-well plate and allowed to attach for 1 h.
Laminin-coated (10 μg/ml) Millicel® culture inserts then
were laid in these wells, and 200,000 TK+ cells were seeded
on these inserts. This system allowed TK+ and TK- cells to
grow in physically distinct compartments but in the same
medium that could be supplemented with 10 μM GCV and/or
0.5 mM Sulfasalazine. After 48-72 h, TK- cells were rinsed in
PBS, trypsinized, and counted in a Thomas cytometer. The
experiments were run three times in duplicate.
Western blot experiments. Western blots were performed as
described elsewhere (16). Briefly, whole cells protein
extracts were separated on 12.5% Tris-HCl polyamide gels
(Bio-Rad, Nazareth, Belgium), transferred on a PVDF
membrane (Amersham) and probed with monoclonal
antibodies to FAS-L (B&D, NOK-1), FAS (Santa-Cruz)
and/or Actin (Santa Cruz). A secondary, HRP-coupled, anti-
mouse antibody (Santa Cruz) was then used for the secondary
step and reveled using a chemiluminescent substrate
(Amersham).
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In vivo experiments. Fifty thousand C6 mixed with 2% of C6-
TK cells were stereotactically implanted in the striatum of 5-
week old Balb-c nude mice and allowed to grow for 3 days.
Mice were then treated for one week with daily intra-
peritoneal injections of saline (control group), ganciclovir
(100 mg/kg), Sulfasalazine (15 mg/kg) or Sulfasalazine +
ganciclovir. Forty mice were included in the protocol (i.e., 10
animals per group). Animals were sacrificed on day 30 and
the brains immediately fixed in formalin. The brains were cut
in consecutive 1-mm thick slices using an adult mice brain
coronal slicer (WPI, Sarasota, FL), stained with cresyl violet
and photographed using a Zeiss Axiocam camera mounted on
a Zeiss stereoscopic magnifying loupes system. The tumor
contours and surface measurements were performed using the
NIH ImageJ (version 1.33u) software. Volumes were
obtained by multiplication of the individual tumor surfaces by
their constant 1-mm thickness. Statistical analyses were
performed using Statview Version 5.0 software (SAS
institute).
Results
Effects of Sulfasalazine on the toxicity of GCV in glioma
cells. Sulfasalazine significantly increased the sensitivity of
TK-expressing LN18, C6 and 9L glioma cells to GCV. In
LN18-TK cells and after 72 h of treatment with GCV, survival
in control conditions was 54±6.34% but only 16.7±7.8% in
the presence of Sulfasalazine. The survival of C6-TK cells
after 48 h of treatment with GCV alone was 81.9±5.4% of
that in control wells. but decreased to 70.6±8.6% with
Sulfasalazine co-treatment. In 9L-TK treated for 72 h with
GCV, survival decreased from 57.3±3.5% in control
conditions to 46.2±1.6% in the presence of Sulfasalazine
(n=3, p<0.05, paired Student's t-test for all cell lines, Table I). 
The survival following GCV treatment of U87-TK cells
for 72 h was, however, unaffected by Sulfasalazine treatment
(86.4±4.1% in control conditions versus 85.5±12.7% in the
presence of Sulfasalazine).
Effects of Sulfasalazine on the bystander effect of cells grown
in contact. Sulfasalazine slightly but significantly increased
the HSV-TK/GCV bystander effect in LN18, C6 and 9L cells.
In cultures of LN18 and 10% LN18-TK cells (9:1 cultures)
grown for 5 days in the presence of GCV (10 μM), the
overall mortality augmented significantly from 19.1±4.4% to
45.62±15% after treatment with Sulfasalazine (0.5 mM). In
98:2 cultures of C6 and C6-TK cells grown for 48 h in the
presence of GCV (10 μM), mortality increased from 0.4±1.5%
in control to 8.3±2% in the presence of Sulfasalazine. In
9L cells cultured for 3 days with 10% of 9L-TK cells and
treated with 10 μM GCV, the overall mortality increased
from 20.1±6.5% to 31.2±0.8% in the presence of 0.5 mM
Sulfasalazine (n=3, p<0.05, Student's t-test for all cell lines). 
However, in 9:1 cultures of U87 and U87-TK cells grown
for 5 days, the overall mortality in control conditions was
38.1±1.6% but decreased to 17.7±11.2% in the presence of
Sulfasalazine (Fig. 1, p<0.05, paired Student's t-test).
Sulfasalazine does not alter gap junction intercellular
communication (GJIC) in glioma cells. Using a FACS analysis
of the intercellular transfer of calcein dye in C6, 9L, U87 and
LN18 cells, we could not evidence any effect of Sulfasalazine
on the intercellular communication (Fig. 2A and data not
shown). 
Effects of GCV and Sulfasalazine on NF-κB nuclear binding
activity in glioma cells. We found that in C6-TK, 9L-TK and
LN18-TK cells the constitutive NF-κB nuclear activity was
increased after ganciclovir treatment but returned to baseline
following low-dose (0.5 mM) Sulfasalazine treatment. In
U87-TK cells, we did not observe any GCV-related activation
of NF-κB, nor did we observe any major inhibition of the
baseline NF-κB activity (Fig. 2B and data not shown). 
Sulfasalazine treatment can unveil a contact-independent
bystander effect in gliomas. TK+ and TK- glioma cells were
grown in bi-compartmental culture devices where they were
physically separated by a porous membrane. The treatment
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Table I. Effect of Sulfasalazine on the toxicity of GCV in
glioma cells.
–––––––––––––––––––––––––––––––––––––––––––––––––
Cell type Treatment Survival Paired Student's
(%) t-test
––––––––––––––––––––––––––––––––––––––––––––––––– 
LN18-TK CTRL 54±6.32 -
Sulfasalazine 16.7±7.8 <0.05
C6-TK CTRL 81.9±5.4 -
Sulfasalazine 70.6±8.6 <0.05
9L-TK CTRL 57.3±3.5 -
Sulfasalazine 46.2±1.6 <0.05
U87-TK CTRL 86.4±4.1 -
Sulfasalazine 85.5±12.7 NS
––––––––––––––––––––––––––––––––––––––––––––––––– 
Figure 1. Effect of Sulfasalazine on the bystander effect of glioma cells grown
in contact. Wild-type LN18, C6, 9L or U87 cells were mixed with their
respective TK-expressing counterparts and grown in the presence or absence
of ganciclovir and/or sulfasalazine (10 μM). After a period of time indicated
in the chart, total cell survival was assessed in each condition with the MTT
test. The overall mortality represents the difference of survival between
GCV-treated and GCV-free wells, expressed as percentage (*p<0.05).
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of such co-cultures with GCV did not alter the survival of
LN18, C6, 9L or U87 cells, meaning that the bystander effect
in these glioma cells is contact-dependent. Co-treatment with
Sulfasalazine and GCV, however, unveiled a bystander effect
in LN18, C6 and 9L cells but not in U87 cells. In such co-
cultures, LN18 cell survival decreased from 99.4±24.5% in
GCV-treated wells to 51.2±10.6% in GCV + Sulfasalazine-
treated wells after 72 h. The survival of C6 cells grown for
48 h in such bi-compartmental cultures decreased from
106.1±15.4% in GCV wells to 62±12.7% in the presence of
GCV and Sulfasalazine. In 9L/9L-TK co-cultures, 9L cell
survival similarly decreased from 104.8±4.6% to 61.1±13.9%
(for each cell type, n=3, p<0.05, Student's t-test). In U87/
U87-TK co-cultures, however, survival of U87 cells after
72 h of treatment with GCV was 97.9±4.3% in control wells
versus 94.9±10.3% in the presence of Sulfasalazine (NS,
Student's t-test, Fig. 3A).
Sulfasalazine did not alter the toxicity of GCV on wild-
type (i.e., TK-) C6, LN18, 9L or U87 cells (data not shown),
suggesting that the observed loss of survival in C6, LN18 and
9L cells grown in bi-compartmental cultures and in the
presence of Sulfasalazine and GCV was indeed dependent
on the presence of their TK-expressing counterparts in the
second culture compartment. To test this hypothesis further,
conditioned medium of LN18-TK, C6-TK, 9L-TK and U87-TK
cells treated or not with Sulfasalazine and/or GCV was
added in cultures of wild-type LN18, C6, 9L or U87 cells.
Conditioned medium of LN18-TK cells treated with GCV for
72 h hardly reduced the survival of LN18 cells onto which it
was transferred for another 24 h (94.2±1.6% of controls).
Medium conditioned by GCV+Sulfasalazine treated LN18-TK
cells, however, strongly decreased the survival of LN18
cells to 52.1±14% after such transfer. Conditioned medium
of C6-TK cells treated for 48 h with GCV did not reduce
the survival of wild-type C6 cells (105.3±4.5%), whereas the
survival of C6 cells was reduced to 67.6±8.9% when the
conditioned medium was obtained from Sulfasalazine and
GCV-treated C6-TK cells. In similar experiments with 9L
cells, the 24-h survival decreased from 103.8±7.8% in GCV-
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Figure 2. Effect of Sulfasalazine on the GJIC and NF-κB binding activity in
glioma cells. A, CMTMR and Calcein-loaded LN18 cells were mixed and
cultured for 4 h with or without Sulfasalazine. FACS analysis was then
performed allowing the simultaneous measurement of CMTMR and Calcein
fluorescence. The proportions of CMTMR loaded cells in which Calcein has
diffused (right upper quadrants) is a measure of the GJIC. B, NF-κB binding
activity in the nuclei of LN18-TK and U87-TK cells following treatment
with ganciclovir and Sulfasalazine for 24 h (<>, specific NF-κB binding
activity).
Figure 3. Effect of sulfasalazine on the contact-independent bystander effect
of glioma cells. A, Survival of wild-type LN18, C6, 9L and U87 cells grown
in bi-compartmental devices where the second compartment contained their
respective TK-expressing counterparts. Survival was obtained by the trypan-
blue exclusion method and is expressed as a percentage with respect to similar
cultures grown without ganciclovir, both with and without the adjunction of
Sulfasalazine in the culture medium (*p<0.05). B, MTT-assessed survival
of wild-type LN18, C6, 9L and U87 cells grown for 24 h in medium
conditioned in their respective TK-expressing counterparts in the presence
or not of ganciclovir and Sulfasalazine (*p<0.05).
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only conditioned medium to 79.7±9% in Sulfasalazine +
GCV-conditionned medium (n=3, p<0.05, Student's t-test).
On the contrary, the survival of U87 cells remained unchanged
when grown in medium conditioned by GCV or GCV +
Sulfasalzine treated U87-TK cells (Fig. 3B). 
Caspase-8 inhibitor Z-IETD-FMK inhibits the bystander
effect in glioma cells. The caspase-8 inhibitor ZIETD-FMK
(20 μM) significantly reduced the bystander effect in co-
cultures of C6 and C6-TK cells. The overall survival of C6
cells cultured for 5 days with 10% of C6-TK cells and
treated with GCV increased from 23.4±5.7% to 44.8±8.8%
in the presence of Z-IETD-FMK (n=3, p<0.05, Student's t-
test). Used as a control, the cathepsin inhibitor Z-FA-FMK
(20 μM) did not alter this bystander effect significantly. A
similar inhibition of the bystander effect by Z-IETD-FMK
was observed in LN18 cells cultured with 50% of LN-TK
cells and treated with GCV. Under these conditions, the
overall cell survival increased from 36.8±11.7% to
71.6±23.8% (n=3, p<0.05, Student's t-test).
Addition of the caspase-8 inhibitor Z-IETD-FMK (30 μM)
also significantly inhibited the toxicity of the conditioned
medium of Sulfasalazine and GCV-treated LN18-TK cells
on LN18 cells. The 24-h survival of LN18 cells grown in
conditioned medium from LN18-TK cells treated with GCV
and Sulfasalazine increased from 61.1±4.6% to 80.1±5.6%
when Z-IETD-FMK was added to the conditioned medium
immediately before its transfer to LN18 cells (n=3, p<0.05,
Student's t-test, Fig. 4A).
Sulfasalazine enhances the toxicity of TNF-· on LN18 and U87
cells but not that of soluble FAS-L. Sulfasalazine (0.5 mM)
significantly increased the toxicity of TNF-· on both U87
and LN18 human glioma cells as measured by the MTT test.
The treatment of LN18 cells with TNF-· (50 or 500 UI/ml)
for 24 h barely reduced the survival of these cells (mortality:
4.2±6.5 and 5.17±11.2% respectively). In the presence of
Sulfasalazine, however, the TNF-induced cell mortality
reached 24.7±9.4 and 35.3±8.4% respectively. Likewise,
the treatment of U87 cells with Sulfasalazine increased the
toxicity of TNF-· (100 or 1000 UI/ml) from 4.1±4.7 and
6.7±2.67% to 26.6±7.6 and 33.1±17% respectively (n=3,
p<0.05, Student's t-test, Fig. 4B and data not shown). 
Sulfasalazine (0.5 mM) also significantly increased the
cytotoxic action of the FAS activating antibody APO1-3 on
LN18 cells. After 24 h, a 1:50 (v:v) dilution of this antibody
reduced the survival of LN18 cells by only 7.6±13.5%. In
the presence of Sulfasalazine, this antibody significantly
reduced the survival of LN18 cells by 65.1±10.7% (n=3,
p<0.05, Student's t-test). Sulfasalazine significantly protected
LN18 cells against soluble FAS-L as the survival of LN18
cells treated with 50 ng/ml sFAS-L increased from 54.9±12.9
to 89.9±15.4% in the presence of Sulfasalazine (n=3, p<0.05,
Student's t-test).
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Figure 4. Role of TNF-· in the contact-independent bystander effect of LN18 cells. A, Effect of the caspase-8 inhibitor on the Sulfasalazine-induced contact-
independent bystander effect of LN18 cells grown in medium conditioned in LN18-TK cells. Experiments were performed as in Fig. 3B. B, Effect of
Sulfasalazine on the toxicity of TNF-· on LN18 cells. Survival was measured by an MTT test. The mortality represents the difference in percentage between
the survival in the presence or absence of TNF-·. C, Secretion of TNF-· in the culture medium of LN18-TK cells and U87-TK cells after ttreatment with
GCV and/or Sulfasalazine fo 96 h. TNF-· concentrations were measured by ELISA and are expressed relative to the concentration of TNF-· measured for
each cell type in the absence of any treatment. D, Effect of a blocking antibody to TNF-· on the Sulfasalazine-unveiled contact-independent bystander effect
of LN18 cells grown in medium conditioned in LN18-TK cells. Experiments were performed as in Fig. 3B.
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GCV treatment increases the secretion of TNF-· in TK-
expressing LN18 glioma cells but not in U87-TK cells. Both
LN18-TK and U87-TK cells were found to secrete TNF-· in
their culture medium. Treatment of LN18-TK cells with GCV
(10 μM) in serum-free medium more than doubled the
secretion of TNF-· within 96 h, and Sulfasalazine co-treatment
even increased this phenomenon (n=3, p<0.05, ANOVA). On
the contrary, GCV treatment significantly inhibited by half
the secretion of TNF-· in U87-TK conditioned media, and
this effect was enhanced by Sulfasalazine co-treatment (n=3,
p<0.01, ANOVA, Fig. 4C). 
Quantitative RT-PCR also reproducibly demonstrated a
moderate increase of TNF-· mRNA in LN18 cells after 24 h of
treatment with GCV. TNF-· mRNA content, however,
remained unchanged in U87 upon such treatment (data not
shown).
A blocking antibody to TNF-· inhibits both the contact-
dependent and contact-independent bystander effect in LN18
human glioma cells. The addition of increasing concentrations
of a blocking antibody to TNF-· significantly and dose-
dependently inhibited the bystander effect in LN18 cells grown
in contact with LN18-TK cells at the ratio of 8:2. Indeed, the
addition of 40 ng/ml of blocking antibody to the culture
medium increased the overall survival of such cultures after
5 days from 47.3±6.9 to 67.8±12.3% (p<0.05, ANOVA with
Tukey-Kramer Multiple comparison test). Similarly, the
addition of this antibody to Sulfasalazine + GCV-treated
LN18-TK conditioned medium prior to its transfer onto
LN18 cells dose-dependently and significantly inhibited the
contact-independent bystander effect (for details, see Fig. 4D;
n=3, p<0.05, ANOVA).
In vivo effect of Sulfasalazine on the growth of C6 tumors
containing 2% C6-TK cells. Fifty thousand C6 and C6-TK
cells at the ratio of 98:2 were stereotactically implanted in
the striatum of nude mice. After 3 days, the mice were given
daily injections of a normal saline solution, ganciclovir (GCV),
Sulfasalazine or a combination of these drugs for 1 week and
sacrificed after another 3 weeks. The resulting tumor size
was significantly reduced in all treatment groups with respect to
controls. The tumor size was further reduced in Sulfasalazine-
treated and sulfasalzine+GCV-treated animals with respect
to GCV-treatment alone. There was, however, no significant
difference in the mean tumor size of Sulfasalazine alone and
sulfasalzine + GCV treatment groups (n=10 in each group,
p<0.05, ANOVA, Fig. 5).
Discussion
In this work, we studied the effect of the NF-κB inhibitor
Sulfasalazine on the efficacy and bystander effect of HSV-TK/
ganciclovir gene therapy for malignant gliomas. The inhibition
of NF-κB has been shown to potentiate the effect of a variety
of cytotoxic treatments including radiation therapy (25-27),
chemotherapy (28) and more recently HSV-TK/ ganciclovir
gene therapy in glioblastoma (29). We found that GCV
treatment activated NF-κB in C6, 9L and LN-18 TK-
expressing cells but not in U87-TK cells, and that Sulfasalazine
both suppressed this activation and sensitized C6, 9L and
LN-18 TK-expressing cells to GCV toxicity. Moriuchi et al
recently showed that concomitant I-κB gene therapy also
increased the action of HSV-TK/GCV gene therapy in U87
cells, which we failed to observe with Sulfasalazine
treatment. This difference may originate from a less complete
inhibition of NF-κB binding activity in our experiments at the
dose of Sulfasalazine used for these cells, or by the existence
of NF-κB independent actions of Sulfasalazine on apoptosis
in glioma cells (19).
We also found that Sulfasalazine treatment augmented the
bystander effect in C6, 9L and LN-18 cells but not in U87
cells. As this increase did not correlate with an enhanced
GJIC between glioma cells in response to Sulfasalazine
treatment, we sought to clarify whether soluble factors could
account for it. Both bi-compartmental cultures and conditioned
medium transfer experiments showed that such a mechanism
indeed developed following treatment with Sulfasalazine in
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Figure 5. Effect of Sulfasalazine and GCV on the in vivo growth of
chimaeric C6/C6-TK tumors. Fifty thousand C6 cells mixed with 2% C6-TK
cells were injected in the striatum of nude mice (day 0). The animals were
treated for 1 week with a normal saline solution, GCV alone, Sulfasalazine
alone or ganciclovir + Sulfasalazine between days 3 and 10 and allowed to
grow for 30 days. The mean volume of tumors in each treatment condition is
shown in the graph. Pictures of animals representative of each treatment
group are shown at the lower end of the figure. Note the size of the transcranial,
subcutaneous growth of tumors in the CTRL and GCV alone conditions
with respect to that of Sulfasalazine or Sulfasalazine + GCV treated mice
(arrowheads).
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two rat (C6 and 9L) and one human (LN18) glioma cell lines.
This finding is to the best of our knowledge the first report of
a medium-diffusible bystander effect in glioma cells using
the same strains of TK- and TK+ cells. We had, however,
observed a similar mechanism in DHD-K12 colon cancer
cells (7), and conditioned medium of TFG10.2-TK cells
treated with GCV was shown to be toxic to C6 cells (6).
Again, U87 cells did not elicit any contact-independent
bystander effect.
We then assessed the role of caspase-8 inhibition on our
models of bystander effect, since death receptors and their
ligands can participate in HSV-TK/ganciclovir induced cell
death and enhance the efficacy of this suicide gene therapy
(12,13,30,31). Treatment with the caspase-8 inhibitor Z-
IETD-FMK indeed inhibited the contact-dependent bystander
effect in C6 and LN18, as well as the contact-independent
bystander effect in LN18 cells. 
As members of the death receptor superfamily can induce
apoptosis through a caspase-8 dependent pathway, we
investigated whether the cytotoxic activity of two secreted
activators of these receptors, TNF-· and soluble FAS-L
(sFAS-L), was increased after Sulfasalazine treatment.
Indeed, this drug sensitized glioma cells to TNF-·, an effect
that is likely due to its anti-NF-κB properties (17). The toxicity
of sFAS-L on the contrary was decreased following treatment
with Sulfasalazine, an effect that has previously been reported
and is likely NF-κB independent (19). TNF-· mRNA
transcription and protein secretion were also augmented in
LN18-TK cells in response to GCV treatment, but decreased
in U87-TK cells that lacked any contact-independent
bystander effect. A blocking antibody to TNF-· dose-
dependently inhibited the contact-independent bystander
effect in LN18 cells. Taken together, these data on LN18 and
U87 cells demonstrate that TNF-· can mediate a contact-
independent bystander effect in HSV-TK/GCV gene
therapy in the presence of Sulfasalazine. While the
transcription factor NF-κB is a potential regulator of TNF-·
synthesis (32), the opposite effect of GCV treatment on the
secretion of TNF-· in LN18-TK and U87-TK is unlikely due
their differential NF-κB response to this drug. Indeed,
Sulfasalazine treatment abolished the GCV-induced
activation of NF-κB in LN18-TK cells but further increased
the secretion of TNF-· by these cells. The precise mechanisms
that underlie the difference of behaviour of LN18 and U87
cells were not studied in the present work.
The generation of a contact-independent bystander effect
has a theoretical interest in the treatment of gliomas with
gene therapy. Indeed, the GJIC of these tumors is highly
variable and often decreased (11), and the physical contact
between glioma cells is hampered by their tendency to migrate
at a distance from the tumoral epicenter (33,34). As our
attempts at growing human LN18 cells in the brains of nude
mice failed, and since Sulfasalazine does not enhance the
bystander effect in human U87 cells, we assessed the in vivo
benefit of Sulfasalazine and HSV-TK/GCV gene therapy
on C6 cell xenografts. GCV treatment alone significantly
decreased the growth of chimeric tumors consisting of
98% of C6 cells and 2% of C6-TK cells. The addition of
Sulfasalazine further and significantly reduced the growth
of such tumors with respect to GCV treatment alone, an
effect that was, however, not different from the effect of
Sulfasalazine alone. We have demonstrated in the past that
Sulfasalazine by itself is a potent inhibitor of glioma growth
(16), and this drug is currently being tested in a phase I/II
clinical protocol as a treatment for recurrent gliomas in
humans (35). Different models of tumors, using diffusely
infiltrative tumors that are less sensitive to the sole action
of Sulfasalazine may thus be needed to truly confirm the
enhancement of the bystander effect by this drug in vivo, but
this is beyond the scope of the present study. Our in vivo
results nonetheless confirm the absence of a drawback and
the potential benefit of adding Sulfasalazine to HSV-TK/
GCV gene therapy in gliomas.
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